<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21395" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ethosuximide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hanrahan</surname>
            <given-names>Brian</given-names>
          </name>
          <aff>Vanderbilt University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Carson</surname>
            <given-names>Robert P.</given-names>
          </name>
          <aff>Vanderbilt University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian Hanrahan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robert Carson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21395.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ethosuximide is a central nervous system agent used to treat absence epilepsy, and this educational session equips healthcare professionals with the necessary information for delivering targeted and personalized care. This activity outlines the indications, actions, and contraindications for ethosuximide, providing essential information for its effective application in clinical settings. The mechanism of action, adverse event profile, dosing guidelines, monitoring requirements, and relevant interactions of ethosuximide are thoroughly reviewed.&#x000a0;A review of this&#x000a0;pharmacological&#x000a0;information assists healthcare professionals in crafting tailored treatment plans that meet individual patient needs, optimizing therapeutic outcomes while minimizing potential adverse reactions.&#x000a0;The discussion focuses on enhancing informed decision-making among healthcare providers during ethosuximide administration. Additionally, this activity highlights the interprofessional healthcare team's crucial role in effectively managing ethosuximide therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate the mechanism of action of ethosuximide.</p></list-item><list-item><p>Identify the indications for ethosuximide therapy.</p></list-item><list-item><p>Assess the most common adverse drug reactions associated with ethosuximide therapy.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from ethosuximide therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21395&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21395">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21395.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ethosuximide is FDA-approved for the management of absence seizures in patients 3 or older.<xref ref-type="bibr" rid="article-21395.r1">[1]</xref>&#x000a0;Additionally, several studies have suggested&#x000a0;ethosuximide may also have some analgesic effects, making it a potential therapy&#x000a0;for neuropathic pain.<xref ref-type="bibr" rid="article-21395.r2">[2]</xref><xref ref-type="bibr" rid="article-21395.r3">[3]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Ethosuximide has demonstrated level A evidence for managing childhood absence seizures and has been effectively&#x000a0;used to treat this condition&#x000a0;since the 1960s.<xref ref-type="bibr" rid="article-21395.r4">[4]</xref><xref ref-type="bibr" rid="article-21395.r5">[5]</xref> A&#x000a0;2010 trial demonstrated that ethosuximide and valproic acid were more effective than lamotrigine&#x000a0;for treating absence seizures.<xref ref-type="bibr" rid="article-21395.r6">[6]</xref>&#x000a0;The seizure freedom rates with initial ethosuximide and valproic acid treatment were 53% and 58%, respectively. These patients were then followed for 12 months to evaluate their long-term outcomes. This study data was published in 2013 and demonstrated ethosuximide has better tolerability than valproic acid.<xref ref-type="bibr" rid="article-21395.r7">[7]</xref>&#x000a0;Ethosuximide has similar efficacy compared to valproic acid in&#x000a0;adolescent patients.<xref ref-type="bibr" rid="article-21395.r8">[8]</xref>&#x000a0;</p>
        <p>Due to its effectiveness and relatively limited&#x000a0;adverse&#x000a0;event profile, ethosuximide is considered the first-line therapy for absence epilepsy. If&#x000a0;absence seizures are refractory to ethosuximide monotherapy, valproic acid can be added to increase the&#x000a0;probability of seizure control.<xref ref-type="bibr" rid="article-21395.r9">[9]</xref> While ethosuximide is effective for absence seizures, it&#x000a0;is typically reserved solely for this condition.&#x000a0;Ethosuximide has demonstrated no benefit in symptomatic epilepsies or other generalized epilepsies. Valproic acid is recommended over ethosuximide as initial monotherapy for patients&#x000a0;with concurrent generalized tonic-clonic (GTC) seizures, as ethosuximide does not help control GTC seizures and can potentially exacerbate them.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>The International League Against Epilepsy (ILAE) recommends ethosuximide for treating neurodevelopmental delay with generalized epilepsy (NDD with generalized epilepsy). This type of epilepsy is characterized by generalized seizure activity along with neurodevelopmental delays and responds well to&#x000a0;medications&#x000a0;like valproate, ethosuximide, or lamotrigine. The ILAE consensus highlights the importance of selecting appropriate treatments based on the specific phenotypes and genetic characteristics of sodium channel neuron 8A (SCN8A)-related disorders. The ILAE recommends&#x000a0;valproic acid&#x000a0;as the initial treatment for epilepsy with eyelid myoclonia (EEM), a condition previously known as Jeavons syndrome.&#x000a0;There is moderate consensus regarding the efficacy of ethosuximide and clobazam in treating this condition. Levetiracetam or lamotrigine are preferred alternatives for women of childbearing age. However, additional randomized controlled trials are required.<xref ref-type="bibr" rid="article-21395.r10">[10]</xref><xref ref-type="bibr" rid="article-21395.r11">[11]</xref></p>
      </sec>
      <sec id="article-21395.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ethosuximide (3-ethyl-3-methyl pyrrolidine-2,5-dione) is&#x000a0;a succinimide agent with anticonvulsant properties. Phensuximide and methsuximide, the other&#x000a0;2 succinimides, have&#x000a0;less favorable adverse effect profiles and lower efficacy than ethosuximide.<xref ref-type="bibr" rid="article-21395.r12">[12]</xref>&#x000a0;This drug class&#x000a0;was first studied in the 1950s&#x000a0;using mouse models.</p>
        <p>Thalamocortical neurons are&#x000a0;thought to use&#x000a0;low-threshold T-type calcium channels to generate the classic 3 Hz "spike-and-wave" discharges&#x000a0;associated with absence seizures.&#x000a0;Ethosuximide can reduce the threshold of T-type calcium currents and disrupt the oscillatory activity of thalamocortical circuitry by blocking T-type calcium channels.<xref ref-type="bibr" rid="article-21395.r13">[13]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Ethosuximide's bioavailability exceeds 90%.</p>
        <p><bold>Distribution:</bold> Ethosuximide&#x000a0;demonstrates&#x000a0;negligible protein binding, readily crosses the blood-brain barrier, and has a distribution volume&#x000a0;of approximately&#x000a0;0.7 L/kg.<xref ref-type="bibr" rid="article-21395.r14">[14]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;Ethosuximide is metabolized&#x000a0;hepatically (80%) into inactive metabolites, primarily by CYP3A4 enzymes.<xref ref-type="bibr" rid="article-21395.r15">[15]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;Approximately 10% to 20% of ethosuximide is excreted unchanged in the urine. If the patient's creatinine clearance falls below 10 mL/min, the dose should be decreased by 25%. Caution is advised&#x000a0;when administering ethosuximide to patients&#x000a0;with hepatic impairment, though no dose adjustments have been defined for these patients.&#x000a0;Ethosuximide&#x000a0;has a relatively long half-life: 30 hours in children and 50 to 60 hours in adults. Because of its long half-life, ethosuximide can take&#x000a0;7 to 10 days to reach steady state.</p>
      </sec>
      <sec id="article-21395.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Ethosuximide is administered using 250 mg capsules or a 250 mg/5 mL oral suspension. The oral suspension&#x000a0;demonstrates&#x000a0;faster absorption than the capsules.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>The typical adult ethosuximide dose is 500 mg orally once daily.&#x000a0;This daily dose&#x000a0;may be increased by 250 mg every 4 to 7 days to a maximum daily dose&#x000a0;of 1500 mg.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;The product labeling does&#x000a0;include dosage adjustments for patients with hepatic impairment. Ethosuximide should be used cautiously for these patients.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;No dosage adjustment is necessary for patients with a creatinine clearance (CrCl) greater&#x000a0;than 30 mL/min. For patients with CrCl less than 30 mL/min, ethosuximide should be&#x000a0;administered&#x000a0;cautiously&#x000a0;using low initial doses.<xref ref-type="bibr" rid="article-21395.r16">[16]</xref>&#x000a0;Patients on hemodialysis may require additional doses before or after their&#x000a0;sessions to maintain therapeutic levels.<xref ref-type="bibr" rid="article-21395.r16">[16]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Ethosuximide is a category C drug (possibly unsafe in pregnancy) known to cross the placenta. Serum concentrations of ethosuximide in neonates are comparable to that of mothers&#x000a0;receiving ethosuximide.<xref ref-type="bibr" rid="article-21395.r17">[17]</xref>&#x000a0;Ethosuximide should be used as monotherapy&#x000a0;at the lowest effective dose possible during pregnancy. Ethosuximide levels&#x000a0;should be obtained before the patient becomes pregnant and monitored during pregnancy. The American Academy of Neurology (AAN), American Epilepsy Society (AES), and Society for Maternal-Fetal Medicine (SMFM) 2024 guidelines&#x000a0;advise that&#x000a0;women who are pregnant (or may become pregnant) with epilepsy on&#x000a0;antiseizure medications (including ethosuximide) should&#x000a0;be informed&#x000a0;of the limited data on pregnancy-related outcomes&#x000a0;associated with&#x000a0;these drugs.<xref ref-type="bibr" rid="article-21395.r18">[18]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Ethosuximide can be excreted in breast milk, making breastfeeding while taking ethosuximide potentially hazardous.&#x000a0;Transfer rates can reach 25%-30% of maternal levels. Close monitoring is recommended for infants exposed to ethosuximide through breast milk. No specific adverse effects have been linked solely to exposure to this medication, but observed adverse effects include drowsiness, impaired feeding, and developmental delays, particularly in younger or exclusively breastfed infants. The potential for additive effects with other maternal anticonvulsants should be considered. Obtaining the infant's serum ethosuximide level can assuage or confirm concerns regarding infant exposure or potential toxicity.<xref ref-type="bibr" rid="article-21395.r19">[19]</xref>&#x000a0;</p>
        <p><bold>Pediatric patients:</bold> According to the American Academy of Neurology (AAN), ethosuximide&#x000a0;or valproic acid are the first-line treatment options for&#x000a0;reducing seizure frequency in patients with childhood absence epilepsy.<xref ref-type="bibr" rid="article-21395.r20">[20]</xref> Dosing should start at 125 mg&#x000a0;twice daily for children aged 3&#x000a0;to 6. Children 6 or older and adults can be administered 250 mg twice daily.&#x000a0;The total daily dose may be increased by 250 mg every 4 to 7 days to 20 mg/kg, divided into twice&#x000a0;daily dosing. The dosing and serum concentrations of ethosuximide demonstrate a linear relationship. When discontinuing,&#x000a0;ethosuximide should be tapered slowly as abrupt withdrawal may cause absence status epilepticus.</p>
        <p><bold>Older patients:</bold>&#x000a0;Ethosuximide is effective for absence seizures in children, but there is limited data on its long-term efficacy and safety in older adults. Agranulocytosis and drug-induced neutropenia have been reported.<xref ref-type="bibr" rid="article-21395.r21">[21]</xref></p>
      </sec>
      <sec id="article-21395.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The overall incidence of adverse effects associated with ethosuximide&#x000a0;therapy is lower compared to most other anti-seizure medications (ASMs).<xref ref-type="bibr" rid="article-21395.r22">[22]</xref>&#x000a0;Gastrointestinal adverse effects (eg, nausea, vomiting, diarrhea, anorexia) are common initially&#x000a0;and often diminish&#x000a0;within 2 weeks. Other&#x000a0;common adverse effects include drowsiness, lethargy, insomnia, and hiccups. Headache&#x000a0;may occur in 14% of children&#x000a0;taking&#x000a0;ethosuximide.&#x000a0;</p>
        <p>Documented&#x000a0;rare idiosyncratic reactions include Stevens-Johnson syndrome, agranulocytosis, aplastic anemia, and systemic lupus erythematosus. If idiosyncratic reactions occur, ethosuximide&#x000a0;should be&#x000a0;discontinued.&#x000a0;Full recovery&#x000a0;may take some time following discontinuation.<xref ref-type="bibr" rid="article-21395.r23">[23]</xref><xref ref-type="bibr" rid="article-21395.r24">[24]</xref> Drug-induced lupus erythematosus&#x000a0;is characterized by anti-histone and antinuclear antibodies.<xref ref-type="bibr" rid="article-21395.r25">[25]</xref>&#x000a0;Priapism has been reported infrequently.<xref ref-type="bibr" rid="article-21395.r26">[26]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Enzyme-inducing ASMs such as phenytoin, carbamazepine, and phenobarbital can reduce serum concentrations of ethosuximide by accelerating its elimination.<xref ref-type="bibr" rid="article-21395.r27">[27]</xref>&#x000a0;Valproic acid has various&#x000a0;effects on ethosuximide concentrations.<xref ref-type="bibr" rid="article-21395.r28">[28]</xref><xref ref-type="bibr" rid="article-21395.r29">[29]</xref><xref ref-type="bibr" rid="article-21395.r30">[30]</xref><xref ref-type="bibr" rid="article-21395.r31">[31]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ethosuximide may increase phenytoin&#x000a0;levels, but it has no enzyme-inducing properties.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Isoniazid may reduce ethosuximide metabolism, while rifampicin can increase ethosuximide clearance.<xref ref-type="bibr" rid="article-21395.r32">[32]</xref><xref ref-type="bibr" rid="article-21395.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>One study indicated that ethosuximide significantly reduced lamotrigine serum concentrations based on patient age. Specifically, children and adolescents treated with ethosuximide showed a 37% reduction in lamotrigine levels compared to 14% in adults.<xref ref-type="bibr" rid="article-21395.r34">[34]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21395.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients with hypersensitivity to succinimide medications should avoid taking ethosuximide.</p>
        <p>
<bold>Warnings and precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ethosuximide should be administered cautiously to patients with hepatic disease, as dosing adjustments for patients with these conditions are undefined.</p>
          </list-item>
          <list-item>
            <p>Antiseizure medications such as ethosuximide increase the risk of suicidal thoughts or behaviors. Patients receiving ethosuximide should be monitored for depression, suicidal ideation, or unusual changes in mood or behavior.<xref ref-type="bibr" rid="article-21395.r35">[35]</xref><xref ref-type="bibr" rid="article-21395.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Ethosuximide can cause drug-induced immune thrombocytopenia (DITP).&#x000a0;<xref ref-type="bibr" rid="article-21395.r37">[37]</xref> DITP typically occurs 1 to 3 weeks after initiation, with recurrence within&#x000a0;24&#x000a0;hours upon re-challenge. Platelet counts may drop by 3,000/mm&#x000b3;. Management involves discontinuation, monitoring platelet counts, and considering antiplatelet antibody assessment. Ethosuximide should be avoided in patients with a history of ethosuximide-induced DITP.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21395.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>There are no guidelines for therapeutic drug monitoring of ethosuximide. Any&#x000a0;ethosuximide dosage adjustment&#x000a0;should be&#x000a0;based on the patient's clinical response and electroencephalography (EEG) results. Ethosuximide levels are monitored by measuring the patient's trough levels. The therapeutic concentration&#x000a0;for ethosuximide&#x000a0;ranges from 40 to 100 &#x003bc;g/mL. Patients with absence status epilepticus may&#x000a0;require&#x000a0;concentrations&#x000a0;above&#x000a0;120 &#x003bc;g/mL to achieve seizure control.<xref ref-type="bibr" rid="article-21395.r14">[14]</xref> A dimple HPLC-UV method has been developed for therapeutic drug monitoring (TDM) of ethosuximide and other&#x000a0;ASM levels.&#x000a0;This method&#x000a0;allows for&#x000a0;the simultaneous determination of ethosuximide alongside several other ASMs and metabolites&#x000a0;and requires only 100 &#x000b5;L of human plasma that may be prepared using a simple process. The dimple HPLC-UV is practical&#x000a0;for pediatric, pregnant, older, and critically ill patients.<xref ref-type="bibr" rid="article-21395.r38">[38]</xref></p>
        <p>A complete blood count (CBC) and liver function tests (LFTs) can also be&#x000a0;obtained&#x000a0;intermittently to monitor for severe but rare hematologic dyscrasias (eg, pancytopenia, agranulocytosis, leukopenia).&#x000a0;However, no evidence&#x000a0;suggests this is sufficient to alert physicians&#x000a0;of a severe idiosyncratic reaction. The pattern of serum enzyme elevations is&#x000a0;typically mixed cholestatic-hepatocellular. Any ethosuximide-induced liver injury resolves quickly&#x000a0;after discontinuing and typically recurs promptly&#x000a0;after re-exposure.<xref ref-type="bibr" rid="article-21395.r15">[15]</xref></p>
      </sec>
      <sec id="article-21395.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Studies using mouse models suggest the earliest symptom of ethosuximide toxicity is ataxia.&#x000a0;Toxic patients&#x000a0;can progress to dyspnea, respiratory failure, and death.<xref ref-type="bibr" rid="article-21395.r39">[39]</xref> In cases of acute ethosuximide overdose in humans, clinical features may include nausea, vomiting, central nervous system depression, and coma with respiratory depression.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There is no antidote for ethosuximide toxicity. Recommendations&#x000a0;involve observation in an emergency room or inpatient setting.<xref ref-type="bibr" rid="article-21395.r40">[40]</xref> Treatment&#x000a0;typically involves the administration of activated charcoal and supportive care.&#x000a0;Hemodialysis can safely and effectively&#x000a0;clear ethosuximide from the body.<xref ref-type="bibr" rid="article-21395.r41">[41]</xref><xref ref-type="bibr" rid="article-21395.r42">[42]</xref></p>
      </sec>
      <sec id="article-21395.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Primary care clinicians are commonly the first medical care providers to be informed about staring episodes or poor school performance. These symptoms suggest absence seizures, prompting a referral to neurology. After diagnosing absence epilepsy and initiating ethosuximide, both primary care physicians and neurologists should monitor for clinical benefit from ethosuximide therapy.&#x000a0;If a patient remains seizure-free for&#x000a0;longer than 2 years while on&#x000a0;ethosuximide, and if the patient's EEG has normalized, the medication may be&#x000a0;slowly tapered over weeks to see if the patient has developed terminal remission.&#x000a0;A pediatric neurologist should be consulted for seizures&#x000a0;refractory to ethosuximide.&#x000a0;</p>
        <p>Ethosuximide is the most effective treatment for new-onset childhood absence epilepsy. However, initial monotherapy fails in 47% of cases.&#x000a0;One pharmacokinetic&#x000a0;study involving 211 participants revealed that area under the curve (AUC) levels of 1,027 and 1,489 &#x003bc;g&#x000b7;h/mL correspond to a 50% and 75% probability of seizure freedom, respectively. Monte Carlo simulations recommend daily doses of 40 and 55 mg/kg. Dosage adjustments based on body weight can enhance the success of the treatment.<xref ref-type="bibr" rid="article-21395.r43">[43]</xref></p>
        <p>Ethosuximide therapy requires an interprofessional healthcare team, including clinicians, nursing staff, pharmacists, and mental health professionals. Nursing can counsel on medications and the disease state and serve as a liaison between other disciplines. Pharmacists should verify dosing, check for potential drug-drug interactions, and guide administration. Specialists&#x000a0;may also&#x000a0;offer their opinions and work with the prescribing clinicians to ensure the patient receives the appropriate therapeutic interventions. An interprofessional team approach and communication among clinicians (MDs, DOs, NPs, PAs), neurologists, pharmacists, and nurses are crucial to decreasing potential adverse effects, improving disease course and quality of life, and improving patient outcomes associated with ethosuximide.</p>
      </sec>
      <sec id="article-21395.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21395&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21395">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21395/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21395">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21395.s11">
        <title>References</title>
        <ref id="article-21395.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flatters</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy.</article-title>
            <source>Pain</source>
            <year>2004</year>
            <month>May</month>
            <volume>109</volume>
            <issue>1-2</issue>
            <fpage>150</fpage>
            <page-range>150-61</page-range>
            <pub-id pub-id-type="pmid">15082137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dogrul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gardell</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Ossipov</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Tulunay</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Porreca</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Reversal of experimental neuropathic pain by T-type calcium channel blockers.</article-title>
            <source>Pain</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>105</volume>
            <issue>1-2</issue>
            <fpage>159</fpage>
            <page-range>159-68</page-range>
            <pub-id pub-id-type="pmid">14499432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamidi</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Ramezani</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Arani</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Talaei</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Mesdaghinia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Banafshe</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide reduces allodynia and hyperalgesia and potentiates morphine effects in the chronic constriction injury model of neuropathic pain.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2012</year>
            <month>Jan</month>
            <day>15</day>
            <volume>674</volume>
            <issue>2-3</issue>
            <fpage>260</fpage>
            <page-range>260-4</page-range>
            <pub-id pub-id-type="pmid">22134003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinstein</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide treatment of petit mal seizures. A study of 87 pediatric patients.</article-title>
            <source>Am J Dis Child</source>
            <year>1966</year>
            <month>Jan</month>
            <volume>111</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-7</page-range>
            <pub-id pub-id-type="pmid">4954419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Browne</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Dreifuss</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Dyken</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Goode</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Penry</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide in the treatment of absence (peptit mal) seizures.</article-title>
            <source>Neurology</source>
            <year>1975</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>515</fpage>
            <page-range>515-24</page-range>
            <pub-id pub-id-type="pmid">805382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Cnaan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirtz</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Dlugos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Masur</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Capparelli</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Adamson</surname>
                <given-names>PC</given-names>
              </name>
              <collab>Childhood Absence Epilepsy Study Group</collab>
            </person-group>
            <article-title>Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Mar</month>
            <day>04</day>
            <volume>362</volume>
            <issue>9</issue>
            <fpage>790</fpage>
            <page-range>790-9</page-range>
            <pub-id pub-id-type="pmid">20200383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Cnaan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirtz</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Dlugos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Masur</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Adamson</surname>
                <given-names>PC</given-names>
              </name>
              <collab>Childhood Absence Epilepsy Study Team</collab>
            </person-group>
            <article-title>Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.</article-title>
            <source>Epilepsia</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-55</page-range>
            <pub-id pub-id-type="pmid">23167925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brigo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Igwe</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Feb</month>
            <day>14</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD003032</fpage>
            <pub-id pub-id-type="pmid">28195639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le Roux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benallegue</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gueden</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rupin-Mas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Bogaert</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Care of pharmaco-resistant absence seizures in childhood.</article-title>
            <source>Rev Neurol (Paris)</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>180</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-255</page-range>
            <pub-id pub-id-type="pmid">38388226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conecker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Hecker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Achkar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cukiert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Devries</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Gardella</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hammer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hegde</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kooistra</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oudin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waldrop</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Youngquist</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wirrell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Global modified Delphi consensus on diagnosis, phenotypes, and treatment of SCN8A-related epilepsy and/or neurodevelopmental disorders.</article-title>
            <source>Epilepsia</source>
            <year>2024</year>
            <month>Aug</month>
            <volume>65</volume>
            <issue>8</issue>
            <fpage>2322</fpage>
            <page-range>2322-2338</page-range>
            <pub-id pub-id-type="pmid">38802994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Wirrell</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Trenit&#x000e9;</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Knupp</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Mugar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nordli</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Riva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Striano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Zawar</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Management of epilepsy with eyelid myoclonia: Results of an international expert consensus panel.</article-title>
            <source>Epilepsia</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>64</volume>
            <issue>9</issue>
            <fpage>2342</fpage>
            <page-range>2342-2350</page-range>
            <pub-id pub-id-type="pmid">37326215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>GOLDENSOHN</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>HARDIE</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>BOREA</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide in the treatment of epilepsy.</article-title>
            <source>JAMA</source>
            <year>1962</year>
            <month>Jun</month>
            <day>09</day>
            <volume>180</volume>
            <fpage>840</fpage>
            <page-range>840-2</page-range>
            <pub-id pub-id-type="pmid">13899742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sills</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Rogawski</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of currently used antiseizure drugs.</article-title>
            <source>Neuropharmacology</source>
            <year>2020</year>
            <month>May</month>
            <day>15</day>
            <volume>168</volume>
            <fpage>107966</fpage>
            <pub-id pub-id-type="pmid">32120063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patsalos</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bourgeois</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Cloyd</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Glauser</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Johannessen</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Leppik</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Tomson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Perucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.</article-title>
            <source>Epilepsia</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>7</issue>
            <fpage>1239</fpage>
            <page-range>1239-76</page-range>
            <pub-id pub-id-type="pmid">18397299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Ethosuximide</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>2</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">31643206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahmoud</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Managing the patient with epilepsy and renal impairment.</article-title>
            <source>Seizure</source>
            <year>2020</year>
            <month>Feb</month>
            <day>10</day>
            <volume>76</volume>
            <fpage>143</fpage>
            <page-range>143-152</page-range>
            <pub-id pub-id-type="pmid">32087549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuhnz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jakob</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Helge</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nau</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide in epileptic women during pregnancy and lactation period. Placental transfer, serum concentrations in nursed infants and clinical status.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1984</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>671</fpage>
            <page-range>671-7</page-range>
            <pub-id pub-id-type="pmid">6508976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pack</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Oskoui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams Roberson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donley</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gerard</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Munger Clary</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Osmundson</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>McFadden</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Parratt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pennell</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Saade</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Tomson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dolan O'Brien</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Botchway-Doe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Silsbee</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Keezer</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM.</article-title>
            <source>Neurology</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>102</volume>
            <issue>11</issue>
            <fpage>e209279</fpage>
            <pub-id pub-id-type="pmid">38748979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Ethosuximide</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanner</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Harden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bourgeois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bautista</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Abou-Khalil</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Burakgazi-Dalkilic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Llanas Park</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirtz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nespeca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gidal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Faught</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Jul</month>
            <day>10</day>
            <volume>91</volume>
            <issue>2</issue>
            <fpage>74</fpage>
            <page-range>74-81</page-range>
            <pub-id pub-id-type="pmid">29898971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lorenzo-Villalba</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alonso-Ortiz</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Maouche</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zulfiqar</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Andr&#x000e8;s</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients.</article-title>
            <source>J Clin Med</source>
            <year>2020</year>
            <month>Jun</month>
            <day>10</day>
            <volume>9</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">32531979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monti Guarnieri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pompilio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ortenzi</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Andresciani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garzone</surname>
                <given-names>AMF</given-names>
              </name>
              <name>
                <surname>Ieracitano</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Polidori</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A pharmacovigilance study on antiepileptic medications in a paediatric hospital in Italy.</article-title>
            <source>Eur J Hosp Pharm</source>
            <year>2023</year>
            <month>Dec</month>
            <day>27</day>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <page-range>46-49</page-range>
            <pub-id pub-id-type="pmid">35410875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Idiosyncratic reactions: new methods of identifying high-risk patients.</article-title>
            <source>Epilepsia</source>
            <year>2000</year>
            <volume>41 Suppl 8</volume>
            <fpage>S16</fpage>
            <page-range>S16-29</page-range>
            <pub-id pub-id-type="pmid">11092609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teoh</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Lupus-scleroderma syndrome induced by ethosuximide.</article-title>
            <source>Arch Dis Child</source>
            <year>1975</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>8</issue>
            <fpage>658</fpage>
            <page-range>658-61</page-range>
            <pub-id pub-id-type="pmid">812426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaya Akca</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sener</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Batu</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Balik</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Basaran</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bilginer</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ozen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced lupus erythematosus in childhood: Case-based review.</article-title>
            <source>Lupus</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>737</fpage>
            <page-range>737-748</page-range>
            <pub-id pub-id-type="pmid">38580326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petrovi&#x00107;</surname>
                <given-names>NZ</given-names>
              </name>
              <name>
                <surname>Pej&#x0010d;i&#x00107;</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Milovanovi&#x00107;</surname>
                <given-names>IR</given-names>
              </name>
            </person-group>
            <article-title>Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-78</page-range>
            <pub-id pub-id-type="pmid">38062555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giaccone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bartoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gatti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marchiselli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pisani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Latella</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Perucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1996</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>575</fpage>
            <page-range>575-9</page-range>
            <pub-id pub-id-type="pmid">8799524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bauer</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wilensky</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Raisys</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide kinetics: possible interaction with valproic acid.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1982</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>741</fpage>
            <page-range>741-5</page-range>
            <pub-id pub-id-type="pmid">6804151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pisani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Narbone</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Trunfio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>La Rosa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Oteri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Perri</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Valproic acid-ethosuximide interaction: a pharmacokinetic study.</article-title>
            <source>Epilepsia</source>
            <year>1984</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>229</fpage>
            <page-range>229-33</page-range>
            <pub-id pub-id-type="pmid">6423377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattson</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Cramer</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Valproic acid and ethosuximide interaction.</article-title>
            <source>Ann Neurol</source>
            <year>1980</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>583</fpage>
            <page-range>583-4</page-range>
            <pub-id pub-id-type="pmid">6776874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Battino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cusi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Franceschetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moise</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Avanzini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide plasma concentrations: influence of age and associated concomitant therapy.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1982</year>
            <season>Mar-Apr</season>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-80</page-range>
            <pub-id pub-id-type="pmid">6802548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bachmann</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jauregui</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo.</article-title>
            <source>Xenobiotica</source>
            <year>1993</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>307</fpage>
            <page-range>307-15</page-range>
            <pub-id pub-id-type="pmid">8498093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Wieringen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vrijlandt</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide intoxication caused by interaction with isoniazid.</article-title>
            <source>Neurology</source>
            <year>1983</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>1227</fpage>
            <page-range>1227-8</page-range>
            <pub-id pub-id-type="pmid">6684262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagemann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Herting</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klimpel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bien</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Polster</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide lowers lamotrigine serum concentrations: Evidence for a clinically relevant interaction.</article-title>
            <source>Epilepsia</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>e73</fpage>
            <page-range>e73-e78</page-range>
            <pub-id pub-id-type="pmid">38606683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chien</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide-induced mania in a 10-year-old boy.</article-title>
            <source>Epilepsy Behav</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>483</fpage>
            <page-range>483-5</page-range>
            <pub-id pub-id-type="pmid">21689989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Datta</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>The impact of anti-seizure medications on psychiatric disorders among children with epilepsy: Both a challenge and an opportunity?</article-title>
            <source>J Can Acad Child Adolesc Psychiatry</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>177</fpage>
            <page-range>177-184</page-range>
            <pub-id pub-id-type="pmid">37534124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shatara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Regling</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sabo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taub</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Rajpurkar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ethosuximide-induced Thrombocytopenia: A Case Report.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>420</fpage>
            <page-range>420-421</page-range>
            <pub-id pub-id-type="pmid">30212418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milosheska</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ro&#x00161;kar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Simple HPLC-UV Method for Therapeutic Drug Monitoring of 12 Antiepileptic Drugs and Their Main Metabolites in Human Plasma.</article-title>
            <source>Molecules</source>
            <year>2023</year>
            <month>Nov</month>
            <day>28</day>
            <volume>28</volume>
            <issue>23</issue>
            <pub-id pub-id-type="pmid">38067559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>CHEN</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>WESTON</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>BRATTON</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Anticonvulsant activity and toxicity of phensuximide, methsuximide and ethosuximide.</article-title>
            <source>Epilepsia</source>
            <year>1963</year>
            <month>Mar</month>
            <volume>4</volume>
            <fpage>66</fpage>
            <page-range>66-76</page-range>
            <pub-id pub-id-type="pmid">14020499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCrea</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antiepileptic drug overdose.</article-title>
            <source>Emerg Nurse</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>13</fpage>
            <page-range>13-8</page-range>
            <pub-id pub-id-type="pmid">11845727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marbury</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Perchalski</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wilder</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Hemodialysis clearance of ethosuximide in patients with chronic renal disease.</article-title>
            <source>Am J Hosp Pharm</source>
            <year>1981</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>1757</fpage>
            <page-range>1757-60</page-range>
            <pub-id pub-id-type="pmid">7304633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wells</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gummin</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Hemodialysis enhances elimination of ethosuximide in massive overdose.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>60</volume>
            <issue>9</issue>
            <fpage>1078</fpage>
            <page-range>1078-1079</page-range>
            <pub-id pub-id-type="pmid">35894638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21395.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mizuno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Capparelli</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adamson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Blumer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cnaan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vinks</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Glauser</surname>
                <given-names>TA</given-names>
              </name>
              <collab>Childhood Absence Epilepsy Study Group</collab>
            </person-group>
            <article-title>Model-Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence Epilepsy.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>114</volume>
            <issue>2</issue>
            <fpage>459</fpage>
            <page-range>459-469</page-range>
            <pub-id pub-id-type="pmid">37316457</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
